• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Dai­ichi Sankyo con­cedes an ear­ly set­back on Duchenne MD drug, but dou­bles down on de­vel­op­ment

8 years ago
R&D

Af­ter decades in the big leagues, Mar­tin Mack­ay is go­ing small — and he's de­light­ed

8 years ago
People
Financing

Celldex brings out the ax in wake of breast can­cer drug dis­as­ter, chop­ping a quar­ter of its staff

8 years ago
R&D
Pharma

'Site-less' tri­als in mind, No­var­tis launch­es an app for oph­thal­mol­o­gy re­search

8 years ago
Pharma

Can Take­da ac­tu­al­ly close its $65B deal to buy Shire? Maybe, but an­a­lysts aren't sure they should

8 years ago
Deals
Pharma

Done deal? Take­da reach­es a ‘break­through’ in Shire merg­er talks as deal an­nounce­ment looms — Reuters

8 years ago
Deals

Ar­rest­ed and charged with fraud, Pixar­Bio CEO Frank Reynolds could face up to 20 years in prison

8 years ago
People

SCO­TUS to bio­phar­ma: In­ter partes re­views are here to stay, deal with it

8 years ago
Pharma

Sofinno­va leads $32.4 mil­lion round for Italy's Ery­Del; Cel­gene ex­pands col­lab­o­ra­tion with Zymeworks

8 years ago
News Briefing

Biotech stars Schleifer and Yan­copou­los share $52M in 2017 com­pen­sa­tion, even though Re­gen­eron's share price swooned

8 years ago
People

Shire says Take­da has come up with a new buy­out of­fer as re­ports spot­light a loom­ing hand­shake deal

8 years ago
Deals

Pro­tein degra­da­tion 2.0? Third Rock sinks $56M in­to Cedil­la's un­usu­al ap­proach

8 years ago
Financing
Startups

Nex­tech leads a $56M round for the Rev­o­lu­tion's move in­to the clin­ic

8 years ago
Financing

As­traZeneca’s Imfinzi/treme­li­mum­ab com­bo fiz­zles again on lung can­cer

8 years ago
R&D

Long­time Sanofi R&D chief Elias Zer­houni is on his way out, hand­ing the re­search reins to Roche vet John Reed

8 years ago
People
R&D

FDA or­ders a par­tial hold on Epizyme’s lead can­cer drug tazeme­to­stat fol­low­ing T-cell lym­phoma case

8 years ago
R&D

FDA pan­el of­fers a wa­ver­ing thumbs up for Eli Lil­ly's 2 mg baric­i­tinib, thumbs down on 4 mg

8 years ago
Pharma

Bank­rupt and weary, di­et pill mak­er Orex­i­gen to sell for $75M to Nal­pro­pi­on

8 years ago
Deals
R&D

The un­der-40s: How does the next gen­er­a­tion of bio­phar­ma ex­ec­u­tives view the fu­ture?

8 years ago
People
Special

Sanofi los­es its Ger­man CSO and di­a­betes chief to Grü­nen­thal; Roche touts longterm ad­van­tages of Ocre­vus in treat­ing ...

8 years ago
News Briefing

EMA com­mit­tee rec­om­mends Al­ny­lam's ear­ly-stage AT­TR amy­loi­do­sis drug for or­phan sta­tus

8 years ago
Pharma

Pfiz­er hits stum­bling block on Her­ceptin ri­val, but wins 'break­through' sta­tus on MenB vac­cine

8 years ago
R&D
Pharma

Sage files for an ap­proval for its ‘break­through’ ther­a­py for post­par­tum de­pres­sion

8 years ago
Pharma

Pen­ny stock biotech Syn­thet­ic Bi­o­log­ics sees its 'break­through' sta­tus pulled as FDA pon­ders safe­ty is­sues

8 years ago
Pharma
First page Previous page 1044104510461047104810491050 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times